Holen Sie sich die Stockscreener-App
14.72
3.59%
0.51
Handel nachbörslich:
14.67
-0.05
-0.34%
Schlusskurs vom Vortag:
$14.21
Offen:
$14.01
24-Stunden-Volumen:
11.49M
Relative Volume:
0.87
Marktkapitalisierung:
$6.67B
Einnahmen:
$285.55M
Nettoeinkommen (Verlust:
$-353.86M
KGV:
-15.49
EPS:
-0.9501
Netto-Cashflow:
$-305.02M
1W Leistung:
+10.59%
1M Leistung:
+57.26%
6M Leistung:
+285.34%
1J Leistung:
+557.14%
1-Tages-Spanne:
$13.80
$14.74
1-Wochen-Bereich:
$13.29
$14.94
52-Wochen-Spanne:
$1.76
$15.30
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
14.72 | 6.67B | 285.55M | -353.86M | -305.02M | -0.9501 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-24 | Fortgesetzt | Goldman | Buy |
| 2026-02-25 | Hochstufung | Citizens | Mkt Perform → Mkt Outperform |
| 2025-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-16 | Herabstufung | UBS | Buy → Neutral |
| 2025-05-12 | Herabstufung | Truist | Buy → Hold |
| 2025-05-09 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Zacks Investment Research
Iovance Biotherapeutics, Inc. (IOVA) Stock Price, News, Quote & History - Yahoo! Finance Canada
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
Iovance Biotherapeutics (LSE:0JDK) Stock Forecast & Analyst Predictions - Simply Wall Street
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - The Manila Times
Iovance Biotherapeutics Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer - GlobeNewswire Inc.
Iovance's new medical chief led programs that helped drive a drug above $2 billion in annual sales. - Stock Titan
IOVA Stock Hits 52-Week High on Raised Revenue Outlook for 2026 - Zacks Investment Research
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains? - Zacks Investment Research
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Forecast & Analyst Predictions - Simply Wall Street
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Moomoo
Iovance Biotherapeutics' Chief Regulatory Officer Reports RSU Vesting and Tax Withholding Transactions - Kalkine Media
Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com Australia
Iovance at Wells Fargo conference: sales momentum lifts outlook By Investing.com - Investing.com UK
Iovance Biotherapeutics (IOVA) Institutional Ownership 2026 - MarketBeat
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - Stocktwits
How Iovance Biotherapeutics Inc. (IOVA) Affects Rotational Strategy Timing - Stock Traders Daily
Iovance Biotherapeutics, Inc. (IOVA) Latest Press Releases & Corporate News - Yahoo Finance
Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewswire
NFLX: Netflix Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Iovance Biotherapeutics (IOVA) Stands Out with Strong Quant Rati - GuruFocus
Iovance Biotherapeutics (IOVA) Wins FDA Trial Clearance, Is The Stock Still 54% Undervalued? - sahmcapital.com
Iovance Biotherapeutics Inc. (IOVA) Peer Comparison – Compare with Others - Value Research
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Eastern Progress
Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates - Eastern Progress
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Biotech company Iovance grants 20 new employees options with an $8.99 exercise price - Stock Titan
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 5.8%Here's Why - MarketBeat
IOVA Stock Pulls Back As Biotech Momentum Cools - StocksToTrade
UBS Lifts Iovance Biotherapeutics Price Target as Cancer Drug Sales Top Expectations - TIKR.com
Iovance Biotherapeutics Stock Is Trending Friday: What's Going On? - Benzinga
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today? - TradingView
Iovance Biotherapeutics grants inducement stock options to 27 new employees - scanx.trade
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Yahoo Finance
Iovance Shares Rise 12.5% as Analyst Price Targets Lag Behind Rally - TechStock²
IOVA Stock Hits Fresh 52-Week Peak On UBS Target Hike, Melanoma Sector Optimism - Stocktwits
Iovance Biotherapeutics stock trends on sector momentum, Q2 beat - scanx.trade
Why Iovance Biotherapeutics Stock Hit 52-Week High - TradingView
IOVA Maintained by UBS -- Price Target Raised to $7.00 - GuruFocus
Iovance's Growth Outlook Clouded as Amtagvi Faces Competition Hurdles, UBS Says - marketscreener.com
META_TITLE_QUOTE - Yahoo Finance
IOVA Stock Climbs As Earnings Beat Fuels Guidance Rethink - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Marks Major Market Shift - Kalkine Media
Here's Why Iovance Biotherapeutics (IOVA) is a Great Momentum Stock to Buy - Yahoo Finance
Iovance Biotherapeutics: Breakout Quarter, Catalysts Ahead, And Competitor Updates (IOVA) - Seeking Alpha
UBS raises Iovance Biotherapeutics stock price target on revenue beat By Investing.com - Investing.com Canada
Iovance Biotherapeutics (NASDAQ:IOVA) Reaches New 12-Month HighWhat's Next? - MarketBeat
IOVANCE BIOTHERAPEUTICS INC : UBS RAISES TARGET PRICE TO $7 FROM $4 - webull.com
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BILINSKY IGOR | Chief Operating Officer |
Sep 08 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
146,050 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 08 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
260,842 |
| Vogt Frederick G | Interim CEO & General Counsel |
Sep 01 '26 |
Option Exercise |
0.00 |
41,669 |
0 |
604,161 |
| Puri Raj K. | Chief Regulatory Officer |
Sep 01 '26 |
Option Exercise |
0.00 |
5,470 |
0 |
253,584 |
| BILINSKY IGOR | Chief Operating Officer |
Sep 01 '26 |
Option Exercise |
0.00 |
8,789 |
0 |
142,709 |
| Kirby Daniel Gordon | Chief Commercial Officer |
Aug 10 '26 |
Option Exercise |
0.00 |
10,001 |
0 |
156,947 |
| Roche Corleen M. | Chief Financial Officer |
Aug 06 '26 |
Option Exercise |
0.00 |
49,995 |
0 |
49,995 |
| Vogt Frederick G | Interim CEO & General Counsel |
Jun 05 '26 |
Option Exercise |
0.00 |
15,625 |
0 |
569,130 |
| GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
7,813 |
0 |
144,087 |
| Puri Raj K. | Chief Regulatory Officer |
Jun 05 '26 |
Option Exercise |
0.00 |
9,766 |
0 |
251,957 |
3.86%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):